drugset / Trial / NCT06426160

Summary

This placebo-controlled study will investigate the effect of tocilizumab (an anti-interleukin-6 receptor antibody) on symptom burden, physical functioning, and quality of life in patients with chronic pancreatitis.

Timeline

Start
2024-05-21
Primary completion
2026-06
Completion
2026-06

Drugs

EvaluationDrugModalityDoseRoute
Comparator Tocilizumab Monoclonal antibody 8 mg/kg

Indications